Skip to main content
    D

    Dare Bioscience Inc (DARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.43
    -0.16 (-26.57%)

    Market Cap: $12.93M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Dare Bioscience Inc (DARE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Dare Bioscience (DARE) has a market cap of $12.93M and an enterprise value of $1.40M. It kept -749.82% of revenue as net income over the last 12 months. Its share count is up 36.59% from a year earlier.

    Total Valuation

    Enterprise value is 89.18% below the market cap, as cash exceeds debt.

    Market Cap$12.93M
    Enterprise Value$1.40M
    Latest price (Nov 17, 2026)$0.43

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 17.00% in the quarter ended Sep 30, 2026 and grew 42.88% a year over 2 years.

    Shares Outstanding17.42M
    Shares Change (YoY)+36.59%
    Shares Change (QoQ)+17.00%
    Share Count Growth (2Y CAGR)+42.88%

    Valuation Ratios

    Sales and book value multiples are 5.3x and 3.2x.

    P/S Ratio5.3x
    Forward P/S4.7x
    P/B Ratio3.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 0.2x free cash flow.

    EV / Sales1.0x
    EV / FCF0.2x

    Price Statistics

    The stock is down 76.94% over 52 weeks and trades 40.28% below its 50-day average.

    Beta (1Y)1.44
    52-Week Change-76.94%
    1-Month Change-39.24%
    3-Month Change-47.96%
    6-Month Change-80.93%
    5-Year Change-96.01%
    10-Year Change-99.27%
    Total Return (1Y)-76.94%
    Total Return (3Y CAGR)-52.93%
    Total Return (5Y CAGR)-53.27%
    Max Drawdown (1Y)-86.88%
    Max Drawdown (3Y)-94.14%
    Sharpe Ratio (1Y)-1.30
    Correlation with SPY (1Y)0.18
    50-Day Average$0.72
    200-Day Average$1.50
    52-Week Range$0.58 to $3.78
    RSI (14 Days)22.5
    Average Volume (20 Days)181.55K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.23x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.23x
    Quick Ratio1.23x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -451.97% and return on assets is -47.89% over the last 12 months.

    Return on Equity (ROE)-451.97%
    Return on Assets (ROA)-47.89%
    Return on Capital Employed (ROCE)-129.85%
    ROA (5Y Average)-68.26%
    Asset Turnover0.05x

    Scores

    DARE has an Altman Z-Score of -13.69, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-13.69
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $1.41M over the last 12 months.

    Revenue$1.41M
    Gross Profit$372.81K
    Operating Income-$10.53M
    Pretax Income-$10.89M
    Net Income-$10.58M
    EBITDA-$8.72M
    EBIT-$10.89M
    Reported EPS (TTM)-$0.68

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 10.59% of the $22.10M in total assets.

    Cash and Equivalents$11.53M
    Total Debt$0
    Net Cash$11.53M
    Net Cash Per Share$0.66
    Working Capital$3.21M
    Shareholder Equity$2.34M
    Book Value Per Share$0.13
    Total Assets$22.10M
    Total Liabilities$19.76M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $489.15K of capital spending, operating cash flow left -$18.19M of free cash flow.

    Operating Cash Flow-$17.70M
    Capital Expenditures$489.15K
    Free Cash Flow-$18.19M
    FCF Per Share-$0.92
    Depreciation and Amortization$2.17M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -746.14%.

    Gross Margin26.42%
    Operating Margin-746.14%
    Pretax Margin-771.52%
    Net Margin-749.82%
    EBITDA Margin-617.60%
    EBIT Margin-771.52%
    FCF Margin-1288.82%

    Dividends and Yields

    DARE does not pay a dividend. Its free cash flow yield is -243.37%.

    FCF Yield-243.37%
    Buyback Yield-95.85%
    Shareholder Yield-95.85%

    Stock Splits

    The last split was a 1-for-12 reverse split on Jul 1, 2024.

    Last Split DateJul 1, 2024
    Split TypeReverse split
    Split Ratio1:12

    Analyst Forecast

    Consensus estimates put revenue growth at 167.97% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+167.97%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DARE

    What is DARE's market cap?

    Dare Bioscience has a market cap of $12.93M. Its enterprise value, which adds debt and subtracts cash, is $1.40M.

    How many shares of DARE are outstanding?

    Dare Bioscience has 17.42M shares outstanding. The count is up 36.59% from a year earlier.

    Does DARE pay a dividend?

    No. Dare Bioscience does not pay a dividend.

    How much debt does DARE have?

    Dare Bioscience has $0 of total debt and $11.53M of cash and equivalents, a net cash position of $11.53M.